CompoAtlas

PROCURVES+ / U-BODY BUST / 500COSMETICS BUST / ONTTOLABS BUST

Integratore alimentare dichiarato in Francia, notifica n. 2019-6-429, decisione del 13 giugno 2019

PROCURVES+ / U-BODY BUST / 500COSMETICS BUST / ONTTOLABS BUST, dell'azienda Natural Logistics S.L, è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Ingredienti principali: Foeniculum vulgare 200 mg al giorno, Trigonella foenum-graecum 200 mg al giorno, Pueraria montana 200 mg al giorno, Serenoa repens 200 mg al giorno, Piper nigrum 100 mg al giorno. 1 punto della sua composizione richiede una verifica (sostanza vietata, dose o nuovo alimento). 4 norme d’uso si applicano ai suoi ingredienti (limiti e avvertenze).

Marca
non indicata
Responsabile dell’immissione in commercio
Natural Logistics S.L
Stato
Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)
Forma
Capsula
Dose giornaliera

Testo originale in francese.

2 comprimés par jour

Compl’Alim, dichiarazioni di integratori alimentari ·

Modalità d’uso

Testo originale in francese.

prendre 2 comprimés par jour avec un repas

Compl’Alim, dichiarazioni di integratori alimentari ·

Popolazioni destinatarie
Donne
Sconsigliato (secondo il fabbricante)
Donne che allattano, Pregresso tumore al seno, Bambini (sotto i 12 anni), Bambini piccoli (da 1 a 3 anni), Donne in gravidanza, Lattanti (sotto 1 anno)
Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)
Antiossidante, Pelle

Notifica 295997, procedura Article 15. Compl’Alim, dichiarazioni di integratori alimentari, consultato il 15 novembre 2026.

Composizione dichiarata

Piante

PiantaPartePreparazioneAl giorno
Foeniculum vulgare Mill.Parties aériennesPoudre (de plantes séchées ou broyées)200 mg
Trigonella foenum-graecum L.GrainePoudre (de plantes séchées ou broyées)200 mg
Pueraria montana var. lobata (Willd.) Sanjappa & PradeepRacinePoudre (de plantes séchées ou broyées)200 mg
Serenoa repens (W.Bartram) SmallFruitPoudre (de plantes séchées ou broyées)200 mg
Piper nigrum L.FruitPoudre (de plantes séchées ou broyées)100 mg
Humulus lupulus L.InflorescencePoudre (de plantes séchées ou broyées)50 mg
Avena sativa L.GrainePoudre (de plantes séchées ou broyées)50 mg
Cnicus benedictus L.Parties aériennesPoudre (de plantes séchées ou broyées)50 mg

Altri ingredienti attivi

NomeAl giorno
Triglycérides à chaine moyennenon dichiarata

Vitamine e minerali

Compl’Alim non pubblica le dosi di vitamine e minerali. I riferimenti qui sotto permettono di leggere l’etichetta del prodotto: limite di sicurezza EFSAAutorità europea per la sicurezza alimentare. per adulti e dose massima fissata in Francia per prodotto (decreto del 9 maggio 2006, non rivisto da novembre 2006).

Forma dichiarataNutrienteLimite EFSA, adulti Dose massima in Francia
Solfato di rameRame5.000 µg2.000 µg
Solfato di manganeseManganese8 mg (livello di sicurezza)3,5 mg
Cloridrato di piridossinaVitamina B612 mg2 mg

Additivi

E122, E460, E551, E171, E464, E463, E110, E341, E470b, E553b

Elenco della dichiarazione, decisione dell'amministrazione del (Compl’Alim, dichiarazioni di integratori alimentari).

Fotografare la confezione

Avvertenze dell’etichetta

Testo originale in francese.

Le E110 et le E122 peuvent avoir des effets secondaires dans l'activité et l'attention des enfants. Les femmes ayant des antécédents personnels ou une patiente atteinte d'un cancer du sein ne doivent pas consommer ce produit. Ne pas prendre si vous êtes âgé de moins de 12 ans. Demander l'avis de votre médecin ou pharmacien.

Compl’Alim, dichiarazioni di integratori alimentari ·

Aspetti normativi

Queste informazioni riprendono la dichiarazione del fabbricante all’amministrazione (DGAL). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Foeniculum vulgare Mill.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    BITTER FENNEL- FOENICULUM VULGARE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Fonti citate da Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condizione di applicazione: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Fonti citate da Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Fonti citate da Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Monografia di Health Canada del 29 novembre 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Fonti citate da Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Fonti citate da Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Monografia di Health Canada del 29 novembre 2024

  • Trigonella foenum-graecum L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    Fonti citate da Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografia di Health Canada del 29 maggio 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 29 maggio 2026

  • Serenoa repens (W.Bartram) Small
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    SAW PALMETTO – SERENOA REPENS

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    Fonti citate da Health Canada (2)
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.

    Condizione di applicazione: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    Fonti citate da Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Controindicazioni

    Condizione di applicazione: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    Fonti citate da Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Monografia di Health Canada del 19 dicembre 2025

  • Humulus lupulus L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    HOPS - HUMULUS LUPULUS

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).

    Fonti citate da Health Canada (2)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.

    Condizione di applicazione: Other uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).

    Fonti citate da Health Canada (4)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2014 : European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 6 Mai 2014. [Consulté le 14 septembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf

    When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).

    Fonti citate da Health Canada (5)
    • EMA 2014: European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 6 May 2014. [Accessed 2023 September 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3e édition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.

    Monografia di Health Canada del 26 aprile 2024

  • Cnicus benedictus L.
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    BLESSED THISTLE - CNICUS BENEDICTUS - Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Controindicazioni

    Do not use if you are pregnant (EMA 2023; Gardner and McGuffin 2013; Bradley 1992; Felter and Lloyd 1983).

    Fonti citate da Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • EMA 2023: EMA/HMPC/32402/2022. European Union herbal monograph on Cnicus benedictus L., herba. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2023 September 20. [Accessed 2025 December 23]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf
    • Felter HW, Lloyd JU. King's American Dispensatory, Volume 1, 18th edition. Sandy (OR): Eclectic Medical Publications; 1983 [Reprint of 1898 original].
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (EMA 2023; Brinker 2010; Blumenthal et al. 2000).

    Fonti citate da Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2023: EMA/HMPC/32402/2022. European Union herbal monograph on Cnicus benedictus L., herba. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2023 September 20. [Accessed 2025 December 23]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf

    Monografia di Health Canada del 30 gennaio 2026

    BLESSED THISTLE - CNICUS BENEDICTUS - Topical

    Precauzioni e avvertenze

    For external use only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 1992; Felter and Lloyd 1983).

    Fonti citate da Health Canada (3)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Felter HW, Lloyd JU. King's American Dispensatory, Volume 1, 18th edition. Sandy (OR): Eclectic Medical Publications; 1983 [Reprint of 1898 original].
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Controindicazioni

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; Blumenthal et al. 2000).

    Fonti citate da Health Canada (2)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Monografia di Health Canada del 28 febbraio 2025

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Elenco rilevato nel 2019. Fotografi la confezione per verificare eventuali modifiche.

Invio per analizzare, Maiusc+Invio per una nuova riga